Rasim Shah

Director at OKRA Technologies at OKRA Technologies

Rasim has dedicated his career of 17 years to pharma and healthcare. He is currently a Director at OKRA Technologies - a leading artificial intelligence (AI) company for life sciences.

He is leading the implementation of AI systems in healthcare, supporting the life sciences industry in bringing the right drug to the right patient at speed. He is passionate about the correct adoption of AI in Europe, and is working with key stakeholders across pharma on crucial drivers of AI, such as evidence, explainability, trust, and ethics.

Himself a patient suffering from a chronic illness for more than 30 years, Rasim is passionate about taking AI out of the labs to help patients in the real world and removing the ‘project mentality’ that exists within life sciences.

Contributing Author in
AI & Digital HealthTech

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Articles from Rasim

COVID-19 Forcing You To Go Digital? You’re Missing A Trick

Moments of crisis always mean change.

In these times, it’s tempting to reach for quotes from leaders who successfully navigated through turbulent times. "Never let a good crisis go to waste," is one often attributed to Churchill and requires us to remain level-headed despite the widespread panic. Companies founded during times of turmoil, like GE, IBM, and Microsoft, know that if they can make their business work during times of upheaval, they can go on to be even more successful in times of stability.

AI For Commercial Life Sciences: 3 Trends You Can’t Ignore In 2020

As we enter a new decade, our belief in the the impact of Artificial intelligence (AI) is only getting stronger. Supporting the industry to drive the right drug to the right patient at speed is a huge responsibility that we take very seriously. Towards the end of the last decade we have seen great progress made within life sciences and the use of AI, but moving into 2020 the spotlight on commercial teams and gaining competitive advantage with AI will intensify.